These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 28462892)

  • 21. Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined.
    Lundgren JR; Janus C; Jensen SBK; Juhl CR; Olsen LM; Christensen RM; Svane MS; Bandholm T; Bojsen-Møller KN; Blond MB; Jensen JB; Stallknecht BM; Holst JJ; Madsbad S; Torekov SS
    N Engl J Med; 2021 May; 384(18):1719-1730. PubMed ID: 33951361
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pleiotropic effects of liraglutide in patients with type 2 diabetes and moderate renal impairment: Individual effects of treatment.
    Zobel EH; von Scholten BJ; Goldman B; Persson F; Hansen TW; Rossing P
    Diabetes Obes Metab; 2019 May; 21(5):1261-1265. PubMed ID: 30663196
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Liraglutide treatment for the prevention of glucose tolerance deterioration in women with prior gestational diabetes mellitus: A 52-week randomized controlled clinical trial.
    Foghsgaard S; Vedtofte L; Andersen ES; Bahne E; Andreasen C; Sørensen AL; Forman JL; Mathiesen ER; Svare JA; Clausen TD; Damm P; Holst JJ; Knop FK; Vilsbøll T
    Diabetes Obes Metab; 2024 Jan; 26(1):201-214. PubMed ID: 37846555
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Liraglutide's Effect on Weight Management in Subjects With Pre-diabetes: A Systematic Review & Meta-Analysis.
    Alsanea S; Alkofide H; Almadi B; Almohammed O; Alwhaibi A; Alrabiah Z; Kalagi N
    Endocr Pract; 2024 Aug; 30(8):737-745. PubMed ID: 38782201
    [TBL] [Abstract][Full Text] [Related]  

  • 25. One-year treatment with liraglutide improved renal function in patients with type 2 diabetes: a pilot prospective study.
    Zavattaro M; Caputo M; Samà MT; Mele C; Chasseur L; Marzullo P; Pagano L; Mauri MG; Ponziani MC; Aimaretti G; Prodam F
    Endocrine; 2015 Dec; 50(3):620-6. PubMed ID: 25572181
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin.
    Cherney DZI; Cooper ME; Tikkanen I; Pfarr E; Johansen OE; Woerle HJ; Broedl UC; Lund SS
    Kidney Int; 2018 Jan; 93(1):231-244. PubMed ID: 28860019
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of vildagliptin in combination with insulin in patients with type 2 diabetes and severe renal impairment.
    Lukashevich V; Schweizer A; Foley JE; Dickinson S; Groop PH; Kothny W
    Vasc Health Risk Manag; 2013; 9():21-8. PubMed ID: 23378769
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Postprandial renal haemodynamic effect of lixisenatide vs once-daily insulin-glulisine in patients with type 2 diabetes on insulin-glargine: An 8-week, randomised, open-label trial.
    Tonneijck L; Muskiet MHA; Smits MM; Hoekstra T; Kramer MHH; Danser AHJ; Diamant M; Joles JA; van Raalte DH
    Diabetes Obes Metab; 2017 Dec; 19(12):1669-1680. PubMed ID: 28449402
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of liraglutide on renal function: A randomized clinical trial.
    von Scholten BJ; Persson F; Rosenlund S; Hovind P; Faber J; Hansen TW; Rossing P
    Diabetes Obes Metab; 2017 Feb; 19(2):239-247. PubMed ID: 27753201
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial.
    O'Neil PM; Birkenfeld AL; McGowan B; Mosenzon O; Pedersen SD; Wharton S; Carson CG; Jepsen CH; Kabisch M; Wilding JPH
    Lancet; 2018 Aug; 392(10148):637-649. PubMed ID: 30122305
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adding liraglutide to lifestyle changes, metformin and testosterone therapy boosts erectile function in diabetic obese men with overt hypogonadism.
    Giagulli VA; Carbone MD; Ramunni MI; Licchelli B; De Pergola G; Sabbà C; Guastamacchia E; Triggiani V
    Andrology; 2015 Nov; 3(6):1094-103. PubMed ID: 26447645
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Benefits of liraglutide treatment in overweight and obese older individuals with prediabetes.
    Kim SH; Abbasi F; Lamendola C; Liu A; Ariel D; Schaaf P; Grove K; Tomasso V; Ochoa H; Liu YV; Chen YD; Reaven G
    Diabetes Care; 2013 Oct; 36(10):3276-82. PubMed ID: 23835684
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function.
    Holtkamp FA; de Zeeuw D; Thomas MC; Cooper ME; de Graeff PA; Hillege HJ; Parving HH; Brenner BM; Shahinfar S; Lambers Heerspink HJ
    Kidney Int; 2011 Aug; 80(3):282-7. PubMed ID: 21451458
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
    Pi-Sunyer X; Astrup A; Fujioka K; Greenway F; Halpern A; Krempf M; Lau DC; le Roux CW; Violante Ortiz R; Jensen CB; Wilding JP;
    N Engl J Med; 2015 Jul; 373(1):11-22. PubMed ID: 26132939
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study.
    Astrup A; Rössner S; Van Gaal L; Rissanen A; Niskanen L; Al Hakim M; Madsen J; Rasmussen MF; Lean ME;
    Lancet; 2009 Nov; 374(9701):1606-16. PubMed ID: 19853906
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of liraglutide treatment on body mass index and weight parameters in children and adolescents with type 2 diabetes: Post hoc analysis of the ellipse trial.
    Bensignor MO; Bomberg EM; Bramante CT; Divyalasya TVS; Hale PM; Ramesh CK; Rudser KD; Kelly AS
    Pediatr Obes; 2021 Aug; 16(8):e12778. PubMed ID: 33634589
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative effects of weight loss and incretin-based therapies on vascular endothelial function, fibrinolysis and inflammation in individuals with obesity and prediabetes: A randomized controlled trial.
    Mashayekhi M; Beckman JA; Nian H; Garner EM; Mayfield D; Devin JK; Koethe JR; Brown JD; Cahill KN; Yu C; Silver H; Niswender K; Luther JM; Brown NJ
    Diabetes Obes Metab; 2023 Feb; 25(2):570-580. PubMed ID: 36306151
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of Efficacy and Safety of Liraglutide 3.0 mg in Individuals with BMI above and below 35 kg/m²: A Post-hoc Analysis.
    le Roux C; Aroda V; Hemmingsson J; Cancino AP; Christensen R; Pi-Sunyer X
    Obes Facts; 2017; 10(6):531-544. PubMed ID: 29145215
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of liraglutide plus phentermine in adults with obesity following 1 year of treatment by liraglutide alone: A randomized placebo-controlled pilot trial.
    Tronieri JS; Wadden TA; Walsh OA; Berkowitz RI; Alamuddin N; Gruber K; Leonard S; Chao AM
    Metabolism; 2019 Jul; 96():83-91. PubMed ID: 30902750
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pancreatic beta cell function following liraglutide-augmented weight loss in individuals with prediabetes: analysis of a randomised, placebo-controlled study.
    Kim SH; Liu A; Ariel D; Abbasi F; Lamendola C; Grove K; Tomasso V; Reaven G
    Diabetologia; 2014 Mar; 57(3):455-62. PubMed ID: 24326527
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.